U.S. Markets closed

DICE Therapeutics, Inc. (DICE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
36.48+0.56 (+1.56%)
At close: 04:00PM EST
37.25 +0.77 (+2.11%)
After hours: 06:52PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close35.92
Bid25.70 x 1100
Ask39.00 x 800
Day's Range35.27 - 37.00
52 Week Range12.64 - 45.99
Avg. Volume932,541
Market Cap1.395B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-11.12
Earnings DateAug 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est66.00
  • Zacks

    Is DICE Therapeutics (DICE) Outperforming Other Medical Stocks This Year?

    Here is how DICE Therapeutics, Inc. (DICE) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.

  • Motley Fool

    These 3 Stocks Are Crushing the Market. Wall Street Thinks They Can Soar at Least 78% Higher.

    The share price of Lantheus Holdings (NASDAQ: LNTH) has nearly doubled in 2022. Much of the gain for the stock came after Lantheus reported its 2021 Q4 results in late February. Lantheus develops imaging diagnostics, targeted therapeutics, and artificial intelligence (AI) solutions for discovering and treating serious medical conditions.

  • GlobeNewswire

    DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights

    Reported positive Phase 1 proof-of-concept data supporting the further development of lead oral IL-17 antagonist, DC-806, as potential best-in-class oral agent for psoriasisDemonstrated direct inhibition of a cytokine with a small molecule in psoriasis patients, which we believe validates the DELSCAPE platform and DICE’s approach to identifying and advancing oral medicines against protein-protein interactions in immunologyCompleted $345 million upsized public offering providing funding into 2026